- 2017 Award in Excellence in Clinical Pharmacology
- 1997 Faculty Awards in Clinical Pharmacology
Dr. Hendrix is a Professor of Medicine, Pharmacology and Molecular Sciences, and Epidemiology The Johns Hopkins University. He has 25 years of experience in the design and conduct of translational clinical pharmacology studies, mostly of antiretroviral drugs for HIV treatment and prevention. He is the Wellcome Professor and Director, Division of Clinical Pharmacology and Director of the Drug Development Unit in the Division. His research focuses on development of antiretroviral drugs to prevent HIV infection and his contributions in this area range from first in human studies to pivotal international multi-center trials. His HIV prevention research has been supported by CDC, NIH, USAID, the Bill and Melinda Gates Foundation, amfAR, and sponsors in the pharmaceutical industry
Dr. Hendrix received his undergraduate degree in Applied Biology at MIT (1978) and his medical degree from Georgetown University, magna cum laude (1984). He completed internship and residency in internal medicine on the Osler Medical Service, and fellowships in Infectious Diseases and Clinical Pharmacology at The Johns Hopkins Hospital. Before joining the Hopkins medical school faculty, Dr. Hendrix served on active duty for 10 years in the U.S. Air Force (USAF) where he was Director of the Air Force HIV Research and Education Program while assigned to Wilford Hall USAF Medical Center in San Antonio, TX (1989-2004), and he developed HIV prevention education programs for the United States military, United Nations Department of Peacekeeping Operations, and other militaries worldwide while assigned to the Division of Retrovirology, Walter Reed Army Institute of Research (1994-1996) and attached to the USAF Surgeon General’s Office (USAF Reserve, 1997-1999).
Dr. Hendrix’s primary research focus the past 15 years has been drug development for chemoprevention of HIV infection with oral, topical, and injectable formulations for the prevention of HIV infection. His group has developed novel methods for the evaluation of topical formulations for HIV pre-exposure prophylaxis combining imaging, multi-compartment pharmacokinetics, and behavioral; assessments in first in human studies. With biostatistical colleagues, he developed a 3-dimensional tube-fitting algorithm to convert SPECT/CT data to concentration v. distance data which, using multiple scans over 24 hours, describes a concentration-distance-time surface to visualize drug product relative to imaging HIV surrogate distribution in the same anatomic space to optimize product formulation development. His group has applied these methods to the early phase development of over 20 different antiretroviral formulations for HIV prevention. In addition, as protocol pharmacologist, he incorporated these methods to support nested PK-PD designs in five of the initial randomized controlled clinical trials of antiretroviral pre-exposure prophylaxis of HIV infection. His group provided an essential contributions to the sNDA for Truvada®’s indication for HIV pre-exposure prophylaxis. PK data from these randomized trials, combined with several smaller studies, has enabled the quantitative assessment of adherence using drug concentrations as an objective adherence measure, providing substantial interpretive power to explain broad heterogeneity of protective response across trials due to large variation in levels of adherence. Subsequently, Dr. Hendrix successfully advocated for real-time testing of adherence in two additional HIV prevention studies (MTN-017 and MTN-020) thus, enabling improved adherence through targeted adherence interventions in the midst of the trials rather than only as an explanatory variable at study end. His research efforts have lead or contributed to over 184 original scientific publications, including 28 in calendar 2016, many of which are in leading peer-reviewed journals including the New England Journal of Medicine (5), Lancet (4), Science, and Cell.
Dr. Hendrix was appointed as the Wellcome Professor and Director, Division of Clinical Pharmacology 1 January 2015. Established in 1954, the Division of Clinical Pharmacology at The Johns Hopkins University School of Medicine is one of the oldest in the world, and has a long history of laboratory and clinical research, teaching, and service activities. At Johns Hopkins University since 1994, Dr. Hendrix also serves as Director of the Drug Development Unit, Lead Pharmacologist for the HIV Prevention Trials Network and Microbicide Trials Network, a Deputy Director of the Hopkins Institute for Clinical and Translational Research (Translational Laboratory Core) and Director of the Hopkins Center for AIDS Research Laboratory Core
Mentoring and teaching medical students, graduate students, and post-doctoral fellows have long been his passion and integral to the success of his own research accomplishments. This past year, he assumed shared leadership of the T32-funded Clinical Pharmacology Training Program at Hopkins. Dr. Hendrix is a recipient of the Johns Hopkins Alumni Association Excellence in Teaching Award and the David M. Levine Faculty Mentoring Award at Hopkins. Seen as a mentoring opportunity to contribute more broadly to rational clinical study design, he has served on the Hopkins institutional review board for the past 16 years
Beyond Hopkins, Dr. Hendrix has served on the FDA Antiviral Drug Products Advisory Committee, Institute of Medicine ad hoc advisory committee, and the Board of Scientific Counselors for the National Center for Infectious Diseases. Dr. Hendrix is Board Certified by the American Board of Clinical Pharmacology and has been an active member of the American Society for Clinical Pharmacology and Therapeutics since the 1997 where he served in multiple leadership positions including the Board of Directors.